Kenneth E. Wolf, Ph.D.
Chief, Communicative Sciences and Disorders
King/Drew Medical Center
Associate Professor of Otolaryngology
Assistant Dean for Educational Affairs
Drew University of Medicine and Science
Los Angeles, California
The first reaction upon reading this case study is
that poor Mrs. Morgan has the misfortune of being covered
by one of those terrible and greedy HMOs that thinks more
of their bottom line than they do about their membersL
needs. However, this case actually illustrates the need
to fully educate the Primary Care Physician (PCP) about
the real meaning of the results of the diagnostic tests
already ordered, and how use of that information may
actually be more cost-effective and lead to a better
clinical outcome than the clinical path chosen.
The audiologist could have telephoned the PCP
immediately upon obtaining these results and explained
that there was a high level of suspicion for
retrocochlear pathology. During the conversation, the
recommendation for an ABR and an ENT consult could have
been made, signaling the potential for a serious medical
condition requiring specialty evaluation/intervention.
The timing of the telephone call demonstrates to the PCP
that the findings call for prompt attention. A written
report follows within 24 hours. If there is still
resistance after voice-to-voice or face-to-face
discussion with the PCP, the audiologist may offer to
provide peer-reviewed evidence to support the need for
further testing and referral. Recommendations for
amplification could have been deferred at this time or
qualified with a statement such as "after suspicion
of retrocochlear pathology has been removed," again,
demonstrating that the medical condition needs action
that takes precedent over selling a hearing aid.
If the above fails, the audiologist should appeal it
to the Utilization Review (UR) team, or higher body
within the HMO. The audiologist should also inform Mrs.
Morgan of his concerns and recommend that she see an ENT
before further pursuit of amplification. The audiologist
runs the risk of irritating the PCP and case manager if
he simply tells Mrs. Morgan to ignore what they have told
her, however, most PCPs are actually receptive to good
information, supported by evidence, especially if it
results in improved outcomes and patient
satisfaction.
The audiologist may fear that alienating the PCP might
reduce or eliminate referrals (but does he really want to
be affiliated with a health care organization that does
not act in its patientLs best interests?). HMOs cannot
"gag" or prevent their providers from telling
their patients the truth about their conditions and
treatments (even though they tried at one time, and
professional codes of ethics and many state statues
prohibited it). However, if a provider is viewed as not
being a team player or shows excessive use of resources
(including referrals and tests that can not be fully
justified with contemporary literature), that HMOLs UR
may stop or reduce referrals and eventually terminate the
contractual agreement.
The audiologist's role to the patient is simple:
full disclosure of the potential problem and that a
retrocochlear problem has not been adequately ruled out.
Simply selling a hearing aid because it has been
authorized when the audiologist knows, based on clinical
data, that this ear has not been established as medically
safe, is unacceptable. The audiologist must serve as the
patientLs advocate in this case, even if other providers
are not, or that there is a potential loss of hearing aid
referrals and sales. The consequences of doing so may be
negative, but then one must ask themselves if they truly
would like this level of service for themselves or their
loved ones? If the answer is NO, and I hope it is, then
does the audiologist really want to be affiliated with an
organization that does business that way? Answering those
questions makes it a lot easier to walk away from an
unfavorable situation.
Remember, most HMOs, contrary to the anecdotal reports
in the popular press, really want their patients to be
well treated and satisfied. It is often less expensive to
treat a patient fully and adequately early-on, then it is
to treat an un- or underserved condition later in the
course of disease. Managed care organizations are willing
to provide the appropriate diagnostic and treatment
services necessary, but in return, they except and demand
evidence to support requests and claims. It is our
obligation, to our patients, our professions, our
colleagues, and our affiliations to provide that
data.
|
Ethics
Roundtable Home
Responses
Annotated Bibliography
|